Paroxetine efficacy in the treatment of generalized anxiety disorder
about
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersAntidepressants for generalised anxiety disorder (GAD)Antidepressants for generalised anxiety disorder (GAD)Generalised anxiety disorderCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersGeneralised anxiety disorder.Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspectiveAnxiety disorders in late life.Anxiety disorder.Measurement of anxiety in transgenic mice.Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)Psychopharmacology of anxiety disorders.Rages and refusals. Managing the many faces of adolescent anxiety.Anxiety disorders and major depression, together or apart.Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders.Serotonergic drugs in the treatment of depressive and anxiety disorders.Treatment of substance abusing patients with comorbid psychiatric disorders.A Review of the Diagnosis, Pharmacologic Treatment, and Economic Aspects of Anxiety Disorders.Psychiatric and Somatic Markers of Anxiety: Identification and Pharmacologic Treatment.Venlafaxine in the treatment of anxiety disorders.Treatments for generalized anxiety disorder.The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis.Paroxetine for somatic pain associated with physical illness: a reviewA cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal.Differential effects of acute and repeated citalopram in mouse models of anxiety and depressionSelective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder.Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder.A Proposed Algorithm for Improved Recognition and Treatment of the Depression/Anxiety Spectrum in Primary Care.Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm".Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications.
P2860
Q22305681-D266B1AC-66D9-4C69-B91A-47C9A820510FQ24186057-F28D6FB9-1D1D-4AD7-8545-8CF463B1352FQ24248715-BB0993EB-DA84-41E0-A20E-DA97B7D729ECQ26863288-0232AE51-563D-479F-924F-1BD8B8C2BE49Q27009995-9643525D-3D04-4418-9B34-4ECAF6040785Q33446789-B7ADAB08-5BE2-4750-B438-805D6431127CQ33629375-D582304C-2BAD-45BD-ABC9-FCE207A42C39Q33787953-F442BEF3-3090-4623-8117-2AE52A6B97DDQ33802854-524EEEFD-8A66-4C18-AE79-F4ED1FA19E5CQ33862518-60C0962B-2539-43C4-A5D7-CF760BCBBE90Q33897936-06C0E5B9-9B4D-4286-AF2D-880EEC1E328BQ34183517-76E2290F-B74E-4FC9-B5D9-2BEC6FFC9C44Q34228150-467FF073-6353-4E87-950F-62FB0558FD0DQ34277730-F1EC9D1D-B7AB-4EFA-AF8D-8316213E599BQ34415535-4095F617-5FB0-46C2-8E33-FCFCF943E624Q34662418-E435305D-02A7-40C3-977B-0613E60194E8Q34982492-EA19B3A2-082F-48DA-9077-9B3520C0AA81Q35387756-B285481D-5B38-424C-84B9-C2DACB969B54Q35666166-73B40529-6EED-4FA1-A40C-6DEC453B21A2Q35666755-20667D0C-E3A4-461D-800A-1054545DAC40Q36106955-779CB1AC-6A02-452F-B3A4-F445BBF3B968Q36107118-37A91342-9AF1-441D-ABD7-F84BC4896E25Q36114391-A52876D8-D61E-45DB-A28F-38C995EB110CQ36567378-034FA568-8882-42C9-B308-778AEA9B2467Q36797810-E85216FA-9714-4F28-92FA-D3ED85335EC6Q36822753-D04A560B-60FD-4696-AE3F-8341221F1B79Q37610268-9024B0E9-6A7E-4D5C-AE36-EDF49DFEA3A9Q38031324-D6F7F9F5-DA1B-4932-B9B3-2C55559854E2Q39853665-8683A0B3-6B29-4CDE-8DEA-4B2A6C0FE942Q45009855-19FFAE29-409B-49A5-B05F-A95007D24A18Q45159165-DB2C0971-23C2-4A88-ABBF-B6E813F6CE8AQ48786821-6C9D0252-6D23-4992-8765-1264C8D7E645
P2860
Paroxetine efficacy in the treatment of generalized anxiety disorder
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Paroxetine efficacy in the treatment of generalized anxiety disorder
@ast
Paroxetine efficacy in the treatment of generalized anxiety disorder
@en
Paroxetine efficacy in the treatment of generalized anxiety disorder
@nl
type
label
Paroxetine efficacy in the treatment of generalized anxiety disorder
@ast
Paroxetine efficacy in the treatment of generalized anxiety disorder
@en
Paroxetine efficacy in the treatment of generalized anxiety disorder
@nl
prefLabel
Paroxetine efficacy in the treatment of generalized anxiety disorder
@ast
Paroxetine efficacy in the treatment of generalized anxiety disorder
@en
Paroxetine efficacy in the treatment of generalized anxiety disorder
@nl
P2093
P2860
P1476
Paroxetine efficacy in the treatment of generalized anxiety disorder
@en
P2093
P2860
P304
P356
10.1111/J.1600-0447.1997.TB09660.X
P407
P577
1997-05-01T00:00:00Z